COX-2 Backlash? Fewer First-Cycle Approvals Would Signal Tougher FDA

A first-cycle drug approval rate significantly lower than 40% could provide the first sign of an effect of COX-2 inhibitor safety issues on FDA reviews, a report from the contract research organization Parexel states